[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR100367A1 - Anticuerpos biespecíficos químicamente bloqueados - Google Patents

Anticuerpos biespecíficos químicamente bloqueados

Info

Publication number
AR100367A1
AR100367A1 ARP150101429A ARP150101429A AR100367A1 AR 100367 A1 AR100367 A1 AR 100367A1 AR P150101429 A ARP150101429 A AR P150101429A AR P150101429 A ARP150101429 A AR P150101429A AR 100367 A1 AR100367 A1 AR 100367A1
Authority
AR
Argentina
Prior art keywords
chemically blocked
antibodies
biespectific
bispecific
igg class
Prior art date
Application number
ARP150101429A
Other languages
English (en)
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of AR100367A1 publication Critical patent/AR100367A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describe un proceso para formar anticuerpos biespecíficos o heterodiméricos químicamente bloqueados, preferentemente en la clase IgG, en elevada especificidad y con elevada homogeneidad. Más específicamente, se describe un anticuerpo de clase IgG biespecífico químicamente bloqueado que tiene una región de ligación unida con química clic bio-ortogonal.
ARP150101429A 2014-05-10 2015-05-11 Anticuerpos biespecíficos químicamente bloqueados AR100367A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461991508P 2014-05-10 2014-05-10

Publications (1)

Publication Number Publication Date
AR100367A1 true AR100367A1 (es) 2016-09-28

Family

ID=54480478

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101429A AR100367A1 (es) 2014-05-10 2015-05-11 Anticuerpos biespecíficos químicamente bloqueados

Country Status (9)

Country Link
US (1) US10435479B2 (es)
EP (1) EP3143154B1 (es)
JP (1) JP6687247B2 (es)
KR (1) KR102460736B1 (es)
CN (1) CN106661602B (es)
AR (1) AR100367A1 (es)
AU (1) AU2015259533B2 (es)
CA (1) CA2948810A1 (es)
WO (1) WO2015175357A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2765242C2 (ru) 2015-08-07 2022-01-27 Имаджинаб, Инк. Антигенсвязывающие конструкции против молекул-мишеней
CA3002073A1 (en) * 2015-10-20 2017-04-27 Sorrento Therapeutics, Inc. Intracellular delivery compounds
CA3005454A1 (en) 2015-11-18 2017-05-26 Sorrento Therapeutics, Inc. Chemically-locked bispecific antibodies
EP3472210A1 (en) 2016-06-17 2019-04-24 Life Technologies Corporation Site-specific crosslinking of antibodies
AU2017319519A1 (en) * 2016-09-01 2019-04-18 Immunomab, Inc. Bispecific antibodies
EP3525824A4 (en) * 2016-10-17 2020-06-10 Shenzhen Enduring Biotech, Ltd. LONG-LASTING MULTI-SPECIFIC MOLECULES AND RELATED PROCEDURES
US20180194859A1 (en) * 2017-01-12 2018-07-12 Sorrento Therapeutics, Inc. Linked Dual Antibodies Conjugated at a Hinge Region
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
CA3097101A1 (en) 2018-04-16 2019-10-24 Nihon Medi-Physics Co., Ltd. Modified antibody and radioactive metal-labelled antibody
WO2024086781A2 (en) * 2022-10-21 2024-04-25 Quantum-Si Incorporated Methods and systems for characterizing phosphoserine-containing polypeptides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185433A (en) * 1990-04-09 1993-02-09 Centocor, Inc. Cross-linking protein compositions having two or more identical binding sites
AU2004308439A1 (en) * 2003-12-22 2005-07-14 Centocor, Inc. Methods for generating multimeric molecules
CN104497143B (zh) * 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
EP2400992B1 (en) 2009-02-27 2015-07-22 Genentech, Inc. Methods and compositions for protein labelling
CN107337734A (zh) 2009-12-04 2017-11-10 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
ME02505B (me) * 2009-12-29 2017-02-20 Aptevo Res & Development Llc Heterodimerni vezujući proteini i njihove upotrebe
WO2012032181A2 (en) 2010-09-10 2012-03-15 Allozyne, Inc Novel antibody derivatives
FI125829B (fi) * 2011-03-07 2016-02-29 Aalto Korkeakoulusã Ã Tiã Double click-teknologia
EP2726494B1 (en) 2011-06-28 2017-01-04 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
WO2013155526A2 (en) * 2012-04-13 2013-10-17 Whitehead Institute For Biomedical Research Sortase- modified vhh domains and uses thereof
US20160326266A1 (en) * 2015-05-10 2016-11-10 Sorrento Therapeutics, Inc. Chemically-Locked Bispecific Antibodies
US20180194859A1 (en) * 2017-01-12 2018-07-12 Sorrento Therapeutics, Inc. Linked Dual Antibodies Conjugated at a Hinge Region

Also Published As

Publication number Publication date
EP3143154B1 (en) 2020-01-29
JP2017518975A (ja) 2017-07-13
WO2015175357A1 (en) 2015-11-19
CA2948810A1 (en) 2015-11-19
US10435479B2 (en) 2019-10-08
AU2015259533B2 (en) 2019-11-28
AU2015259533A1 (en) 2017-01-05
CN106661602A (zh) 2017-05-10
KR20170002622A (ko) 2017-01-06
EP3143154A1 (en) 2017-03-22
EP3143154A4 (en) 2017-11-22
JP6687247B2 (ja) 2020-04-22
KR102460736B1 (ko) 2022-10-31
CN106661602B (zh) 2021-03-30
WO2015175357A9 (en) 2016-04-07
US20170260291A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
AR100367A1 (es) Anticuerpos biespecíficos químicamente bloqueados
ECSP17081420A (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CU20170074A7 (es) Anticuerpos heterodiméricos que se unen a cd3 y a antígenos tumorales
CL2018000744A1 (es) Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso.
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CR20150482A (es) Anticuerpos e inmunoconjugados anti-b7-h4
CR20170383A (es) Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
MX2018005036A (es) Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes.
HUE054384T2 (hu) EGFRVIII-T és CD3-at kötõ bispecifikus antitest-konstrukciók
CU24427B1 (es) Moléculas de anticuerpo que se unen a tim-3
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
UY36889A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
BR112017004614A2 (pt) terapias de combinação com anticorpos anti-cd38
CR20190271A (es) Anticuerpos antitau y métodos de uso
MX2016012124A (es) Anticuerpos contra glicopeptidos inmunogenicos, composicion que los comprende y usos de estos.
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
NZ631098A (en) Anti-hepcidin antibodies and uses thereof
PH12016500940A1 (en) HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
CL2017002596A1 (es) Neutralización del virus chikungunya mediada por anticuerpos
CL2019001352A1 (es) Anticuerpo biespecífico heterodimérico estructural de anticuerpo natural anti-pd-1/anti-her2 y método para preparar el mismo.
CO2017010631A2 (es) Método para purificación de proteína
IL269645A (en) Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
CU24556B1 (es) Anticuerpos anti-basigin humanizados

Legal Events

Date Code Title Description
FB Suspension of granting procedure